{"schema_version":"secwatch.filing_event.v1","accession":"0001645113-23-000045","form_type":"8-K","ticker":"NVCR","cik":"0001645113","company_name":"NovoCure Ltd","filed_at":"2023-07-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.667283+00:00","generated_at":"2026-06-13T00:34:24.111435+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Novocure Q2 net revenue $126M (-11% YoY); phase 3 LUNAR NSCLC trial meets primary endpoint","bullets":["Net loss $57.4M ($0.54 per share); adjusted EBITDA -$27.2M; active patients 3,571.","LUNAR trial: median OS 13.2 months TTFields+standard vs 9.9 months standard alone (HR=0.74, p=0.035).","Revenue decline largely due to $13.4M reduced collections from previously denied U.S. claims.","Prescriptions up 13% to 1,556; U.S., Germany, Japan contributed 981, 204, and 92 respectively.","PANOVA-3 (pancreatic) DMC recommends proceeding to final analysis; LUNAR-2 trial IDE accepted by FDA."],"urls":{"canonical":"https://secwatch.observer/filing/0001645113-23-000045","json":"https://secwatch.observer/filing/0001645113-23-000045.json","markdown":"https://secwatch.observer/filing/0001645113-23-000045.md","text":"https://secwatch.observer/filing/0001645113-23-000045.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645113/000164511323000045/0001645113-23-000045-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645113/000164511323000045/nvcr-20230727.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T00:34:24.111435+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"518f93723dc73cdead220243f1cbaa533dd9cbd1","claim":"NovoCure Ltd reported the quarter ended June 30, 2023 results: revenue $126.1 million, net income $57.4 million, EPS $0.54.","evidence_excerpt":"30, 2023. A copy of the press release is attached as Exhibit 99.1. --- EX-99.1 (EX-99.1) --- Novocure Reports Second Quarter 2023 Financial Results Quarterly net revenues of $126 million with 3,571 active patients on therapy as of June 30, 2023 Phase 3 LUNAR trial in non-small cell lung cancer met primary and key secondary survival endpoints, the first of four","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511323000045/0001645113-23-000045-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Revenue","value":"$126.1 million"},{"label":"Net income","value":"$57.4 million"},{"label":"EPS","value":"$0.54"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}